Nancy J Turner

US Patent:

58665706, Feb 2, 1999

Filed:

Jun 21, 1994

Appl. No.:

8/262888

Inventors:

Chi-Ming Liang - Bethesda MD
Nancy A. Turner - Germantown MD
Donald T. Witiak - Madison WI

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

A61K 31535

US Classification:

5142322

Abstract:

A method for identifying patients at risk of developing vascular leakage syndrome and systemic inflammatory response syndrome (SIRS) such as septic shock by determining the serum levels of metalloproteinase expression, in particular type IV collagenase expression, as well as a method of treating or preventing vascular leakage syndrome and SIRS by the administration of one or more metalloproteinase inhibitors, preferably type IV collagenase inhibitors is taught. Additionally, the therapeutic efficacy of bis(dioxopiperazine) compounds is determined on the basis of collagenase inhibiting activity, and the compounds which inhibit collagenase activity are utilized for the treatment of collagenase related disorders, e. g. , vascular leakage syndrome, septic shock, stroke, cardiac disorders, angiogenesis, and arthritis. Finally, a method for preventing or treating toxicity caused by endogenous cytokine expression or cytokine administration or by immunotoxin administration by the administration of one or more metalloproteinase inhibitors, preferably type IV collagenase inhibitors is taught.